Analyse des signes cliniques des malades atteints de pemphigoïde en fonction des antigènes reconnus par leur sérum en immunotransfert
暂无分享,去创建一个
J. Guillaume | D. Gilbert | M. D’incan | B. Dréno | O. Chosidow | L. Vaillant | P. Plantin | B. Sassolas | C. Bédane | P. Joly | J. Roujeau | P. Joly | B. Labeille | P. Bernard | C. Picard | A. Gary | C. Lok | P. Saiag | E. Delaporte | C. Pauwels | P. Carvalho | E. Tancrède-Bohin | J. Louison | M. Hélot | F. Loche
[1] M. Meurer,et al. Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age. , 2002, Archives of dermatology.
[2] P. Courville,et al. Extensive erosive bullous pemphigoid: an atypical and serious clinical variant , 2002, The British journal of dermatology.
[3] L. Vaillant,et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. , 2002, The New England journal of medicine.
[4] P. Courville,et al. [Evaluation of histological criteria for bullous pemphigoid. Correlation with antigens recognized by immunoblotting of anti-epidermal autoantibodies]. , 2000, Annales de pathologie.
[5] E. Bröcker,et al. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. , 2000, Archives of dermatology.
[6] J. Roujeau,et al. Lichenoid erythrodermic bullous pemphigoid of the African patient. , 1998, Journal of the American Academy of Dermatology.
[7] L. Vaillant,et al. Evaluation of clinical criteria for diagnosis of bullous pemphigoid. French Bullous Study Group. , 1998, Archives of dermatology.
[8] J. Roujeau,et al. High risk of death in elderly patients with extensive bullous pemphigoid. , 1998, Archives of dermatology.
[9] S. M. Ewing,et al. A highly sensitive enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid. , 1997, The Journal of investigative dermatology.
[10] R. Ghohestani,et al. Immunofluorescence-negative bullous pemphigoid sera contain antibodies mostly directed against the 180 kDa bullous pemphigoid antigen (BPAg2) , 1997, The British journal of dermatology.
[11] P. Courville,et al. Relationship between the in vivo localization and the immunoblotting pattern of anti-basement membrane zone antibodies in patients with bullous pemphigoid. , 1997, Archives of dermatology.
[12] J. Bonnetblanc,et al. Anti‐BP180 autoantibodies as a marker of poor prognosis in bullous pemphigoid: a cohort analysis of 94 elderly patients , 1997, The British journal of dermatology.
[13] L. Vaillant,et al. Drugs Associated With Bullous Pemphigoid: A Case-Control Study , 1996 .
[14] T. Nishikawa,et al. Clinical manifestations in 100 Japanese bullous pemphigoid cases in relation to autoantigen profiles , 1996, Clinical and experimental dermatology.
[15] Jean Kanitakis,et al. BPAg2 antibodies are present at lower levels than BPAg1 antibodies in serum from patients with bullous pemphigoid , 1996 .
[16] S. G. Woods,et al. Erythrodermic bullous pemphigoid is a clinical variant of bullous pemphigoid , 1995, The British journal of dermatology.
[17] E. Bröcker,et al. Incidence of autoimmune subepidermal blistering dermatoses in a region of central Germany. , 1995, Archives of dermatology.
[18] L. Vaillant,et al. Incidence and Distribution of Subepidermal Autoimmune Bullous Skin Diseases in Three French Regions , 1995 .
[19] L. Vaillant,et al. Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group. , 1995, Archives of dermatology.
[20] C. Lebbé,et al. Overlapping distribution of autoantibody specificities in paraneoplastic pemphigus and pemphigus vulgaris. , 1994, The Journal of investigative dermatology.
[21] J. Troy,et al. A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. , 1993, The Journal of clinical investigation.
[22] K. Owaribe,et al. HD4, a 180 kDa bullous pemphigoid antigen, is a major transmembrane glycoprotein of the hemidesmosome. , 1993, Journal of biochemistry.
[23] F. Tron,et al. Brunsting-Perry cicatricial bullous pemphigoid: a clinical variant of localized acquired epidermolysis bullosa? , 1993, Journal of the American Academy of Dermatology.
[24] J. Bonnetblanc,et al. Immunoblot analysis of IgG subclasses of circulating antibodies in bullous pemphigoid. , 1990, Clinical immunology and immunopathology.
[25] J. Saurat,et al. Heterogeneous bullous pemphigoid antibodies: detection and characterization by immunoblotting when absent by indirect immunofluorescence. , 1989, The Journal of investigative dermatology.
[26] D. Roop,et al. Isolation of complementary DNA for bullous pemphigoid antigen by use of patients' autoantibodies. , 1988, The Journal of clinical investigation.
[27] N. Ling,et al. Subclass distribution of IgG autoantibodies in bullous pemphigoid. , 1986, The Journal of investigative dermatology.
[28] T. Flotte,et al. Immunoglobulin light and heavy chain isotypes in skin diseases: restricted distribution in bullous pemphigoid and linear IgA bullous dermatosis. , 1986, Journal of immunology.
[29] N. Levine,et al. Localized pemphigoid simulating dyshidrosiform dermatitis. , 1979, Archives of dermatology.
[30] H. Perry,et al. Benign Pemphigoid?: A Report of Seven Cases with Chronic, Scarring, Herpetiform Plaques About the Head and Neck , 1957 .